Robert Campbell Rintoul
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Robert Campbell Rintoul has a total of 1000 co-authors. Here are the top co-authors by number of shared publications:
Doris M. Rassl
Royal Papworth Hospital NHS Foundation Trust, Cambridge Biomedical Campus, Cambridge, UK
13 shared publications- Stefan John Marciniak
Cambridge Institute for Medical Research University of Cambridge Cambridge UK
7 shared publications Andrew G. Nicholson
Dept of Histopathology, Royal Brompton Hospital and Harefield NHS Foundation Trust and National Heart and Lung Institute, London, UK
6 shared publicationsD. Gilligan
Royal Papworth Hospital NHS Foundation Trust, Cambridge, UK; Addenbrooke's Hospital, Cambridge, UK
6 shared publicationsD. Rassl
Papworth Hospital NHS Foundation Trust, Cambridge/GB
6 shared publicationsL. Ashcroft
Christie Hosp Fdn Trust, MAHSC CTU, Manchester, Lancs, England
6 shared publications
Latest Publications
- Open Access
Multiomic analysis of a pleural mesothelioma organoid biobank defines gene dependencies and therapeutic vulnerabilities
Pleural mesothelioma (PM) remains an incurable cancer with few effective therapeutic options and limited understanding of its targetable dependencies, owing in part to a scarcity of clinically relevant, scalable models. Here, we describe establishment of an annotated biobank of 26 patient-derived PM organoids that faithfully recapitulate the clinical, genomic and histopathological landscapes of their parent tumours, including driver mutations, copy-number alterations and mutational signatures. By integrating these organoid models with a complementary collection of low-passage primary PM cell lines, we generate a functional precision oncology platform for PM. Genome-scale CRISPR-Cas9 screening across 23 patient-derived PM models uncovered 1,150 core fitness genes, including 638 not shared with pan-cancer core essentials, highlighting critical requirements for proteostasis, DNA repair, RNA processing and cell-cycle control. Parallel profiling of 106 compounds across 36 PM models revealed broad therapeutic vulnerabilities in proteostasis, growth signalling and epigenetic regulation. Beyond these shared vulnerabilities, both screens uncovered genotype-specific dependencies and drug responses linked to recurrent PM alterations. This functional map of shared and genotype-specific dependencies establishes patient-derived organoids as a scalable platform for precision therapeutic discovery in pleural mesothelioma
Open AccessMultiomic analysis of a pleural mesothelioma organoid biobank defines gene dependencies and therapeutic vulnerabilities
Pleural mesothelioma (PM) remains an incurable cancer with few effective therapeutic options and limited understanding of its targetable dependencies, owing in part to a scarcity of clinically relevant, scalable models. Here, we describe establishment of an annotated biobank of 26 patient-derived PM organoids that faithfully recapitulate the clinical, genomic and histopathological landscapes of their parent tumours, including driver mutations, copy-number alterations and mutational signatures. By integrating these organoid models with a complementary collection of low-passage primary PM cell lines, we generate a functional precision oncology platform for PM. Genome-scale CRISPR-Cas9 screening across 23 patient-derived PM models uncovered 1,150 core fitness genes, including 638 not shared with pan-cancer core essentials, highlighting critical requirements for proteostasis, DNA repair, RNA processing and cell-cycle control. Parallel profiling of 106 compounds across 36 PM models revealed broad therapeutic vulnerabilities in proteostasis, growth signalling and epigenetic regulation. Beyond these shared vulnerabilities, both screens uncovered genotype-specific dependencies and drug responses linked to recurrent PM alterations. This functional map of shared and genotype-specific dependencies establishes patient-derived organoids as a scalable platform for precision therapeutic discovery in pleural mesothelioma
- Open Access
Randomised pilot and feasibility study comparing video-assisted thoracoscopic partial pleurectomy-decortication with indwelling pleural catheter for trapped lung in pleural mesothelioma
MesoTRAP aimed to provide preliminary data comparing the efficacy of indwelling pleural catheter (IPC) versus video-assisted thoracoscopic pleurectomy-decortication for trapped lung in pleural mesothelioma. Trapped lung prevalence was 11% (110/988). Over 31 months, 17 centres randomised 10 patients versus 38 planned. Thirteen non-randomised patients entered an observational substudy. Nine randomised patients reported daily visual analogue scale scores for pain and dyspnoea, but measurements varied substantially within and between patients, precluding meaningful analysis. Slow recruitment due to poor performance status precluding surgery prohibits a full trial. In the absence of high-level evidence, we conclude that the least invasive approach to trapped lung, namely IPC, should be considered in line with current guidance. Trial registration number NCT03412357.
Open AccessRandomised pilot and feasibility study comparing video-assisted thoracoscopic partial pleurectomy-decortication with indwelling pleural catheter for trapped lung in pleural mesothelioma
MesoTRAP aimed to provide preliminary data comparing the efficacy of indwelling pleural catheter (IPC) versus video-assisted thoracoscopic pleurectomy-decortication for trapped lung in pleural mesothelioma. Trapped lung prevalence was 11% (110/988). Over 31 months, 17 centres randomised 10 patients versus 38 planned. Thirteen non-randomised patients entered an observational substudy. Nine randomised patients reported daily visual analogue scale scores for pain and dyspnoea, but measurements varied substantially within and between patients, precluding meaningful analysis. Slow recruitment due to poor performance status precluding surgery prohibits a full trial. In the absence of high-level evidence, we conclude that the least invasive approach to trapped lung, namely IPC, should be considered in line with current guidance. Trial registration number NCT03412357.
- Open Access
- 10 July 2026
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 12 (28) , eady9432
A scalable deep-learning framework for cancer detection using cell-free DNA shallow whole-genome sequencing
Cell-free DNA (cfDNA) in body fluids enables noninvasive cancer detection. Multifeature artificial intelligence (AI) can improve sensitivity by integrating diverse biomarkers when cancer signals are sparse. Tumor-informed assays that rely on mutations have limited practicality for early cancer detection. Emerging fragmentomic and epigenetic features underpin tumor-naive approaches to screening for individuals with low tumor burden. Here, we designed UNITE—a universal cfDNA feature ensemble framework that provides scalable cancer detection methods based on “genomic bin–fragment length” matrices derived from shallow whole-genome sequencing (sWGS) data at 0.1× depth. Using sWGS data from 2063 plasma samples (631 controls and 1432 cases from 26 cancer types), we systematically evaluated both XGBoost (UNITE-XGB) and convolutional neural networks (UNITE-CNN) across multiple feature spaces and cancer stages. In stage I-II cancer, UNITE-XGB and UNITE-CNN achieved 31 and 21% sensitivity, respectively, at 95% specificity. These findings provide roadmaps for developing multifeature AI beyond plasma biopsies.
- 10 July 2026
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 12 (28) , eady9432
Open AccessA scalable deep-learning framework for cancer detection using cell-free DNA shallow whole-genome sequencing
Cell-free DNA (cfDNA) in body fluids enables noninvasive cancer detection. Multifeature artificial intelligence (AI) can improve sensitivity by integrating diverse biomarkers when cancer signals are sparse. Tumor-informed assays that rely on mutations have limited practicality for early cancer detection. Emerging fragmentomic and epigenetic features underpin tumor-naive approaches to screening for individuals with low tumor burden. Here, we designed UNITE—a universal cfDNA feature ensemble framework that provides scalable cancer detection methods based on “genomic bin–fragment length” matrices derived from shallow whole-genome sequencing (sWGS) data at 0.1× depth. Using sWGS data from 2063 plasma samples (631 controls and 1432 cases from 26 cancer types), we systematically evaluated both XGBoost (UNITE-XGB) and convolutional neural networks (UNITE-CNN) across multiple feature spaces and cancer stages. In stage I-II cancer, UNITE-XGB and UNITE-CNN achieved 31 and 21% sensitivity, respectively, at 95% specificity. These findings provide roadmaps for developing multifeature AI beyond plasma biopsies.
- Open Access
- 13 May 2026
- Published by Springer Nature in Nature Aging
- Vol. 6 (5) , 1158-1176
Urinary detection of therapy-induced senescence and fibrosis using an injectable albumin-based nanoprobe
Cellular senescence is a hallmark of age-related disorders, including cancer, in which senescence contributes to tumor progression and treatment resistance. Targeting senescent cells therapeutically requires noninvasive methods to longitudinally monitor senescence burden. Here, we present an injectable nanoprobe for noninvasive detection of therapy-induced senescence in lung cancer and pulmonary fibrosis via urine testing. Using human biopsy samples, clinical transcriptomic datasets and mouse models, we identify matrix metalloproteinase-7 (MMP-7) as a specific biomarker of senescence in lung cancer and bleomycin-induced fibrosis. We develop ALBANC, a nanoprobe composed of human serum albumin linked to gold nanoclusters (AuNCs) through MMP-7-cleavable peptide linkers. MMP-7-mediated cleavage releases AuNCs that are renally excreted, enabling rapid and sensitive colorimetric urine detection via a nanoparticle growth-based assay, enabling longitudinal tracking of cisplatin-induced senescence and senolysis in mouse lung tumors and fibrosis. This approach offers a noninvasive and sensitive precision tool for monitoring senescence burden in lung cancer.
- 13 May 2026
- Published by Springer Nature in Nature Aging
- Vol. 6 (5) , 1158-1176
Open AccessUrinary detection of therapy-induced senescence and fibrosis using an injectable albumin-based nanoprobe
Cellular senescence is a hallmark of age-related disorders, including cancer, in which senescence contributes to tumor progression and treatment resistance. Targeting senescent cells therapeutically requires noninvasive methods to longitudinally monitor senescence burden. Here, we present an injectable nanoprobe for noninvasive detection of therapy-induced senescence in lung cancer and pulmonary fibrosis via urine testing. Using human biopsy samples, clinical transcriptomic datasets and mouse models, we identify matrix metalloproteinase-7 (MMP-7) as a specific biomarker of senescence in lung cancer and bleomycin-induced fibrosis. We develop ALBANC, a nanoprobe composed of human serum albumin linked to gold nanoclusters (AuNCs) through MMP-7-cleavable peptide linkers. MMP-7-mediated cleavage releases AuNCs that are renally excreted, enabling rapid and sensitive colorimetric urine detection via a nanoparticle growth-based assay, enabling longitudinal tracking of cisplatin-induced senescence and senolysis in mouse lung tumors and fibrosis. This approach offers a noninvasive and sensitive precision tool for monitoring senescence burden in lung cancer.
- Open Access
- 14 April 2026
- Published by Royal Society of Chemistry (RSC) in Nanoscale
- Vol. 18 (21) , 11064-11091
Engineering molecularly imprinted polymers for receptor-specific cancer therapeutics
Cancer therapy is often limited by poor tumour selectivity, systemic toxicity, and drug resistance, highlighting the need for advanced nanoscale drug delivery systems that enable precise molecular targeting and controlled therapeutic release.
- 14 April 2026
- Published by Royal Society of Chemistry (RSC) in Nanoscale
- Vol. 18 (21) , 11064-11091
Open AccessEngineering molecularly imprinted polymers for receptor-specific cancer therapeutics
Cancer therapy is often limited by poor tumour selectivity, systemic toxicity, and drug resistance, highlighting the need for advanced nanoscale drug delivery systems that enable precise molecular targeting and controlled therapeutic release.
- Top Cited PapersOpen Access
- 23 March 2026
- Published by Springer Nature in Nature Medicine
- Vol. 32 (5) , 1817-1826
Implementation of the NHS England Lung Cancer Screening Programme over 5 years
Lung cancer screening with low-dose computed tomography has been proven to reduce lung-cancer-specific and all-cause mortality. The UK launched the NHS England Targeted Lung Health Check Programme in 2019, which has now become the national Lung Cancer Screening Programme, with full coverage expected by 2030. Here we present the progress and outcomes of the program. People aged 55–74 were offered low-dose computed tomography of the thorax if they had ever smoked and if risk thresholds, as determined by multivariable models, were met. Delivery of the program is through regionally federated clinical infrastructure and leadership, with national strategic, clinical and economic frameworks. The program has invited over two million people, with 7,193 lung cancers diagnosed—63.1% at tumor, node, metastasis stage 1 and 12.6% stage 2—to March 2025. This has increased the early-stage proportion of lung cancer in England over 5 years, particularly in socioeconomically deprived regions. The NHS England Programme exemplifies how large-scale implementation can be achieved at speed through centralized protocols and effective project management. The program has demonstrated feasibility and scalability in reaching high-risk and underserved populations, but needs to further address inequalities in participation. These findings support adoption of lung cancer screening across the UK and globally, and offer practical tools for international adaptation.
- 23 March 2026
- Published by Springer Nature in Nature Medicine
- Vol. 32 (5) , 1817-1826
Top Cited PapersOpen AccessImplementation of the NHS England Lung Cancer Screening Programme over 5 years
Lung cancer screening with low-dose computed tomography has been proven to reduce lung-cancer-specific and all-cause mortality. The UK launched the NHS England Targeted Lung Health Check Programme in 2019, which has now become the national Lung Cancer Screening Programme, with full coverage expected by 2030. Here we present the progress and outcomes of the program. People aged 55–74 were offered low-dose computed tomography of the thorax if they had ever smoked and if risk thresholds, as determined by multivariable models, were met. Delivery of the program is through regionally federated clinical infrastructure and leadership, with national strategic, clinical and economic frameworks. The program has invited over two million people, with 7,193 lung cancers diagnosed—63.1% at tumor, node, metastasis stage 1 and 12.6% stage 2—to March 2025. This has increased the early-stage proportion of lung cancer in England over 5 years, particularly in socioeconomically deprived regions. The NHS England Programme exemplifies how large-scale implementation can be achieved at speed through centralized protocols and effective project management. The program has demonstrated feasibility and scalability in reaching high-risk and underserved populations, but needs to further address inequalities in participation. These findings support adoption of lung cancer screening across the UK and globally, and offer practical tools for international adaptation.
- Top Cited PapersOpen Access
- 3 February 2026
- Published by Springer Nature in Nature Aging
- Vol. 6 (2) , 368-392
Treatment resistance to platinum-based chemotherapy in lung and ovarian cancer is driven by a targetable TGFβ senescent secretome
Platinum-based chemotherapy is commonly used for non-small cell lung cancer (NSCLC) and high-grade serous ovarian cancer (HGSOC) treatments, yet clinical outcomes remain poor. Cellular senescence and its associated secretory phenotype (SASP) can have multiple tumor-promoting activities, but both are largely unexplored in these cancers. In this study, using xenograft, orthotopic and Kras G12V -driven murine NSCLC models, we demonstrate that cisplatin-induced senescence strongly promotes malignant phenotypes and tumor progression, which is stimulated by aging. Mechanistically, we found that a transforming growth factor-beta (TGFβ)-enriched SASP drives pro-proliferative effects through TGFBR1 and AKT/mTOR. TGFBR1 inhibition with galunisertib or senolytic treatment reduces tumor progression driven by cisplatin-induced senescence, and concomitant use of TGFBR1 inhibitors with platinum-based chemotherapy reduces tumor burden and improves survival. Finally, we validate the translational relevance of tumor-promoting TGFβ-enriched SASP using clinical NSCLC and HGSOC samples from patients who received neoadjuvant platinum-based chemotherapy. Together, our findings identify a potential cancer therapy resistance mechanism and provide preclinical proof of concept for future trials.
- 3 February 2026
- Published by Springer Nature in Nature Aging
- Vol. 6 (2) , 368-392
Top Cited PapersOpen AccessTreatment resistance to platinum-based chemotherapy in lung and ovarian cancer is driven by a targetable TGFβ senescent secretome
Platinum-based chemotherapy is commonly used for non-small cell lung cancer (NSCLC) and high-grade serous ovarian cancer (HGSOC) treatments, yet clinical outcomes remain poor. Cellular senescence and its associated secretory phenotype (SASP) can have multiple tumor-promoting activities, but both are largely unexplored in these cancers. In this study, using xenograft, orthotopic and Kras G12V -driven murine NSCLC models, we demonstrate that cisplatin-induced senescence strongly promotes malignant phenotypes and tumor progression, which is stimulated by aging. Mechanistically, we found that a transforming growth factor-beta (TGFβ)-enriched SASP drives pro-proliferative effects through TGFBR1 and AKT/mTOR. TGFBR1 inhibition with galunisertib or senolytic treatment reduces tumor progression driven by cisplatin-induced senescence, and concomitant use of TGFBR1 inhibitors with platinum-based chemotherapy reduces tumor burden and improves survival. Finally, we validate the translational relevance of tumor-promoting TGFβ-enriched SASP using clinical NSCLC and HGSOC samples from patients who received neoadjuvant platinum-based chemotherapy. Together, our findings identify a potential cancer therapy resistance mechanism and provide preclinical proof of concept for future trials.
- Open Access
Multi-centre discovery and validation study evaluating breath biomarkers for the diagnosis of lung cancer – the LuCID study
Background: Volatile Organic Compound (VOC) research for lung cancer detection has faced study design and analytical methodology challenges limiting translation into clinical practice. We evaluated the diagnostic value of breath biomarkers in patients under investigation for suspected lung cancer. Methods: In a multi-centre prospective case-control study involving 1844 subjects under investigation, breath samples from subjects with a conclusive diagnosis were analysed using gas-chromatography mass-spectrometry. A staged approach was adopted: an Exploratory method for targeted analysis of 63 VOCs associated with lung cancer, followed by an Optimised method for biomarker discovery and finally, evaluation of the optimised panel in a separate validation cohort. Results were compared to the Liverpool Lung Project (LLP) risk model. Findings: Using breath VOCs from 677 controls and 518 cases the Exploratory method showed only 2 literature-reported compounds differed significantly between cases and controls. The Optimised method detected 102 VOCs, with ten differing between cases and controls. However, in a validation cohort the 10-VOC panel differentiated cases from controls cohort with a modest AUC: 0.54±0.14 for early-stage disease, 0.58±0.16 for advanced stage disease and 0.58±0.11 for all cases, which did not differ significantly from the LLP model. Combining VOCs with the LLP model did not significantly improve diagnostic performance (AUC 0.64±0.11). Interpretation: Although some potential biomarkers were identified, their diagnostic performance did not surpass an epidemiological risk model. The study highlights the importance of careful trial design to avoid false-positive findings and indicates a need for more targeted approaches to enhance signal-to-noise ratio in breath biomarker research. Highlights: Largest, to date, multi-centre prospective case-control study evaluating volatile organic compounds (VOC) for intention-to-diagnose lung cancer. Gas chromatography mass spectrometry was used to compare VOCs in lung cancer cases with co-morbidity matched controls. Although some VOCs differentiated cases from controls, diagnostic performance did not surpass an epidemiological risk model. These data explain the challenge of previous studies to validate and translate into clinical practice. A more targeted approach to enhance signal-to-noise ratio is required.
Open AccessMulti-centre discovery and validation study evaluating breath biomarkers for the diagnosis of lung cancer – the LuCID study
Background: Volatile Organic Compound (VOC) research for lung cancer detection has faced study design and analytical methodology challenges limiting translation into clinical practice. We evaluated the diagnostic value of breath biomarkers in patients under investigation for suspected lung cancer. Methods: In a multi-centre prospective case-control study involving 1844 subjects under investigation, breath samples from subjects with a conclusive diagnosis were analysed using gas-chromatography mass-spectrometry. A staged approach was adopted: an Exploratory method for targeted analysis of 63 VOCs associated with lung cancer, followed by an Optimised method for biomarker discovery and finally, evaluation of the optimised panel in a separate validation cohort. Results were compared to the Liverpool Lung Project (LLP) risk model. Findings: Using breath VOCs from 677 controls and 518 cases the Exploratory method showed only 2 literature-reported compounds differed significantly between cases and controls. The Optimised method detected 102 VOCs, with ten differing between cases and controls. However, in a validation cohort the 10-VOC panel differentiated cases from controls cohort with a modest AUC: 0.54±0.14 for early-stage disease, 0.58±0.16 for advanced stage disease and 0.58±0.11 for all cases, which did not differ significantly from the LLP model. Combining VOCs with the LLP model did not significantly improve diagnostic performance (AUC 0.64±0.11). Interpretation: Although some potential biomarkers were identified, their diagnostic performance did not surpass an epidemiological risk model. The study highlights the importance of careful trial design to avoid false-positive findings and indicates a need for more targeted approaches to enhance signal-to-noise ratio in breath biomarker research. Highlights: Largest, to date, multi-centre prospective case-control study evaluating volatile organic compounds (VOC) for intention-to-diagnose lung cancer. Gas chromatography mass spectrometry was used to compare VOCs in lung cancer cases with co-morbidity matched controls. Although some VOCs differentiated cases from controls, diagnostic performance did not surpass an epidemiological risk model. These data explain the challenge of previous studies to validate and translate into clinical practice. A more targeted approach to enhance signal-to-noise ratio is required.
- Open Access
- 15 April 2025
- Published by Public Library of Science (PLoS) in PLOS Medicine
- Vol. 22 (4) , e1004574
Recurrence prediction using circulating tumor DNA in patients with early-stage non-small cell lung cancer after treatment with curative intent: A retrospective validation study
Background: Despite treatment with curative intent, many patients with localized non-small cell lung cancer (NSCLC) develop recurrence. The current challenge is to identify high-risk patients to guide adjuvant treatment. Identification of residual disease by detection of circulating tumor DNA (ctDNA) may allow more accurate clinical decision-making, but its reliability in NSCLC is not established. We aimed to build on previous data to validate a tissue-informed personalized ctDNA assay, to predict recurrence in patients with early-stage disease. Methods and findings: Tumor tissue and plasma was collected from patients with stage 0–III NSCLC enrolled to LEMA (Lung cancer Early Molecular Assessment trial, NCT02894853). Serial plasma was collected before and after definitive treatment, with the latter including key timeframes of interest (1–3 days post-treatment, between 14 and 122 days after treatment end, and ≥14 days after treatment end). Somatic mutations identified by tumor exome sequencing were used to design patient-specific assays, to analyze ctDNA. Results were compared and combined with an independent dataset (LUCID; LUng Cancer CIrculating Tumour Dna study, NCT04153526). In LEMA, 130 patients (57% male; median age 66 years (range 44–82); 69% adenocarcinoma, 22% squamous cell carcinoma (SCC); 3%/49%/19%/29% with stage 0/I/II/III) were treated with curative intent. Tumor tissue originated from surgical resection or diagnostic biopsy in 118 and 12 patients respectively. LUCID included 88 patients (51% male; median age 72 years (range 44–88); 63% adenocarcinoma, 31% SCC; 49%/28%/23% with stage I/II/III). Before treatment, ctDNA was detected in 48% LEMA and 51% LUCID patients. Sensitivity, specificity, positive and negative predictive value of ctDNA detection post-treatment (≥1 positive sample ≥14 days after treatment end) to predict recurrence were 61%, 97%, 92% and 84% for LEMA and 64%, 96%, 90% and 83% for LUCID. In the combined cohort, ctDNA detection after treatment was associated with shorter recurrence-free survival (hazard ratio (HR) 11.4 (95% confidence interval (CI) [7.0,18.7]; p < 0.001)) and overall survival (HR 8.1 (95% CI [4.6,14.2]; p < 0.001)), accounting for guarantee-time bias. Of note, a key limitation of this work was the irregular sample collection schedules, during routine follow-up visits, of both studies. Conclusions: ctDNA detection predicted recurrence in independent retrospective cohorts with notable reproducibility, including near-identical detection rates and predictive values, confirming its ability to differentiate patients at high- versus low risk of recurrence. Our results support the potential of tissue-informed ctDNA analysis as a decision-support tool for adjuvant therapy in NSCLC.
- 15 April 2025
- Published by Public Library of Science (PLoS) in PLOS Medicine
- Vol. 22 (4) , e1004574
Open AccessRecurrence prediction using circulating tumor DNA in patients with early-stage non-small cell lung cancer after treatment with curative intent: A retrospective validation study
Background: Despite treatment with curative intent, many patients with localized non-small cell lung cancer (NSCLC) develop recurrence. The current challenge is to identify high-risk patients to guide adjuvant treatment. Identification of residual disease by detection of circulating tumor DNA (ctDNA) may allow more accurate clinical decision-making, but its reliability in NSCLC is not established. We aimed to build on previous data to validate a tissue-informed personalized ctDNA assay, to predict recurrence in patients with early-stage disease. Methods and findings: Tumor tissue and plasma was collected from patients with stage 0–III NSCLC enrolled to LEMA (Lung cancer Early Molecular Assessment trial, NCT02894853). Serial plasma was collected before and after definitive treatment, with the latter including key timeframes of interest (1–3 days post-treatment, between 14 and 122 days after treatment end, and ≥14 days after treatment end). Somatic mutations identified by tumor exome sequencing were used to design patient-specific assays, to analyze ctDNA. Results were compared and combined with an independent dataset (LUCID; LUng Cancer CIrculating Tumour Dna study, NCT04153526). In LEMA, 130 patients (57% male; median age 66 years (range 44–82); 69% adenocarcinoma, 22% squamous cell carcinoma (SCC); 3%/49%/19%/29% with stage 0/I/II/III) were treated with curative intent. Tumor tissue originated from surgical resection or diagnostic biopsy in 118 and 12 patients respectively. LUCID included 88 patients (51% male; median age 72 years (range 44–88); 63% adenocarcinoma, 31% SCC; 49%/28%/23% with stage I/II/III). Before treatment, ctDNA was detected in 48% LEMA and 51% LUCID patients. Sensitivity, specificity, positive and negative predictive value of ctDNA detection post-treatment (≥1 positive sample ≥14 days after treatment end) to predict recurrence were 61%, 97%, 92% and 84% for LEMA and 64%, 96%, 90% and 83% for LUCID. In the combined cohort, ctDNA detection after treatment was associated with shorter recurrence-free survival (hazard ratio (HR) 11.4 (95% confidence interval (CI) [7.0,18.7]; p < 0.001)) and overall survival (HR 8.1 (95% CI [4.6,14.2]; p < 0.001)), accounting for guarantee-time bias. Of note, a key limitation of this work was the irregular sample collection schedules, during routine follow-up visits, of both studies. Conclusions: ctDNA detection predicted recurrence in independent retrospective cohorts with notable reproducibility, including near-identical detection rates and predictive values, confirming its ability to differentiate patients at high- versus low risk of recurrence. Our results support the potential of tissue-informed ctDNA analysis as a decision-support tool for adjuvant therapy in NSCLC.